Articles from Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights.

Edgewise Therapeutics, Inc. (NASDAQEWTX) today announced the closing of its upsized underwritten public offering of 13,372,093 shares of its common stock at a price to the public of $10.32 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The total gross proceeds from the offering, before deducting underwriters’ discounts and commissions and offering expenses, are $138 million.

Edgewise Therapeutics, Inc., (NASDAQEWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today reported financial results for the second quarter of 2022 and recent business highlights.

Edgewise Therapeutics, Inc., (NASDAQEWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that members of its management team will participate in a fireside chat and one-on-one investor meetings at the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 5:30 p.m. ET.